Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01996774
Other study ID # RC-P0013
Secondary ID
Status Completed
Phase N/A
First received November 22, 2013
Last updated August 18, 2014
Start date February 2012
Est. completion date March 2014

Study information

Verified date August 2014
Source Lille Catholic University
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Observational

Clinical Trial Summary

Many authors propose the strict avoidance of allergenic food as the only treatment for children known to be allergic to certain food. However, it has been observed an increase of the frequency and severity of the allergic accidents in these children in the long term. Other teams have suggested treating these allergies (in particular peanut allergies) by controlled and progressive reintroduction of the allergenic food. A good tolerance and a prevention of allergic reactions consecutive to the ingestion of the same allergenic food were observed. The immunological mechanisms of this type of treatment are not well known.

A decrease of specific IgE and an increase of IgG4 have been observed in the case of egg allergies after this kind of treatment. Certain experiments realized in mice models testing the allergenic stimulation challenge showed an increase of lymphocytes T regulators (foxp3+ , CD4+, CD25+), stimulated by dendritic cells, and also an increase of interleukin 10, leading to the modification of the balance between Th1 and Th2.Our hypothesis is that after treating allergies by the reintroduction of the allergenic food, the immunological mechanism of acquisition of tolerance is associated to variations in populations of lymphocytes and in the activation or decrease of pro and anti-inflammatory cytokines. This reaction will be studied in two groups: 1. Children with a confirmed allergy to peanuts or nuts and 2. Children without antecedents of allergy or familiar atopy.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 1 Year to 17 Years
Eligibility Group 1:

Inclusion Criteria:

- Children (between 1 and 16 years old)known to have an allergy to peanuts and nuts detected by specific IgE, specific recombinant rArah (1 to 8) and R Cora and other allergens with a value superior or equal to 5KU/L.

- Child, parents or legal representatives have given informed consent to participate in the study after being informed in details about the protocol.

Exclusion Criteria:

- Immunodeficiency,

- Children or parents in disagreement with the study

- Children without standard diagnostic test at recruitment (oral provocation test vs. placebo)

- Children who reacted to placebo

- Children with uncontrolled asthma or respiratory disease

- Treatment with oral antihistaminic or corticoids one week before

- Neither Healthcare coverage nor insurance

Group 2:

Inclusion criteria

- Children (between 1 and 16 years old)known to have an allergy to peanuts and nuts detected by specific IgE, specific recombinant rArah (1 to 8) and R Cora and other allergens with a value superior or equal to 5KU/L

- Doubling the values of the threshold after second oral challenge compared to the tests of reference

- Child, parents or legal representatives have given informed consent to participate in the study after being informed in details about the protocol.

Exclusion Criteria:

- Immunodeficiency,

- Children or parents in disagreement with the study

- Children without standard diagnostic test at recruitment (oral provocation test vs placebo)

- Children who reacted to placebo

- Children with uncontrolled asthma or respiratory disease

- Treatment with oral antihistaminic or corticoids one week before

- Neither Healthcare coverage nor insurance

Group 3:

Inclusion criteria:

- Children (between 1 and 16 years old)

- No allergy to peanuts or nuts

- No antecedents of atopia

- Child, parents or legal representatives have given informed consent to participate in the study after being informed in details about the protocol

Exclusion Criteria:

- Immunodeficiency,

- Children or parents in disagreement with the study

- Children without standard diagnostic test at recruitment (oral provocation test vs. placebo)

- Children who reacted to placebo

- Children with uncontrolled asthma or respiratory disease

- Treatment with oral antihistaminic or corticoids one week before

- Neither Healthcare coverage nor insurance

Study Design

Observational Model: Case Control, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
France Groupement des Hôpitaux de l'Institut Catholique de Lille Lomme Nord

Sponsors (1)

Lead Sponsor Collaborator
Lille Catholic University

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Allergen-specific biomarkers in blood and saliva within the 15 days of subject enrollment No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04621916 - Preventing Inhibitor Recurrence Indefinitely Phase 4
Recruiting NCT06243289 - Improving KIdney Transplantation With Cellular Therapy Study
Recruiting NCT03591302 - Delayed Blood Stem Transplantation in HLA Matched Kidney Transplant Recipients to Eliminate Immunosuppressive Drugs. Phase 1
Completed NCT04525456 - Immune Responses With Reduxium N/A
Recruiting NCT04314518 - The Correlation Between Immunological Reaction of the Seminal Fluid in the Mother's Blood and Pregnancy Complications
Enrolling by invitation NCT04571203 - Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment Phase 1
Recruiting NCT01367821 - Immune Function in Patients With Obstructive Jaundice N/A
Enrolling by invitation NCT01117077 - The Immune Tolerance Mechanism Induced by IL-17-producing Regulatory T Cells in the Orthotopic Liver Transplant Recipients With Aspergillosis N/A
Terminated NCT05010174 - Long-term Safety Follow-up in Recipients Who Previously Received Medeor's Cellular Immunotherapy Products
Active, not recruiting NCT03744325 - Immune Responses in Hen's Egg Oral Immunotherapy N/A
Completed NCT03383211 - Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Recruiting NCT02861872 - Intra-peritoneal Chemotherapy in Ovarian Cancer N/A
Active, not recruiting NCT00319657 - Kidney and Blood Stem Cell Transplantation That Eliminates Requirement for Immunosuppressive Drugs Phase 1/Phase 2
Completed NCT01538485 - Vitamin D Supplementation and Regulatory FoxP3+ T Cells in the GUT Phase 4
Completed NCT03393793 - HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Recruiting NCT03292445 - Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation Early Phase 1
Active, not recruiting NCT05745792 - Clinico-immunological Characterization and Immune Tolerance Breakdown in HU-autoimmunity
Completed NCT02642237 - The Effects of Preceding LPS Administration on the Fluenz-induced Immune Response N/A
Completed NCT01414504 - Pneumococcal Conjugate Vaccine Followup Phase 2
Not yet recruiting NCT06147375 - Efficacy and Safety of Immunosuppressive Withdrawal After Pediatric Liver Transplantation N/A